Compare ANGI & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANGI | TARA |
|---|---|---|
| Founded | 1995 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 198.7M | 236.1M |
| IPO Year | 2017 | 2014 |
| Metric | ANGI | TARA |
|---|---|---|
| Price | $4.78 | $3.94 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | $17.00 | ★ $24.40 |
| AVG Volume (30 Days) | ★ 776.8K | 324.7K |
| Earning Date | 05-05-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1242.86 | 38.25 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $736,386,000.00 | $2,948,000.00 |
| Revenue This Year | $3.25 | N/A |
| Revenue Next Year | $3.76 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 47.60 | N/A |
| 52 Week Low | $4.26 | $3.02 |
| 52 Week High | $18.38 | $7.82 |
| Indicator | ANGI | TARA |
|---|---|---|
| Relative Strength Index (RSI) | 46.11 | 47.37 |
| Support Level | $4.57 | $3.73 |
| Resistance Level | $6.52 | $4.17 |
| Average True Range (ATR) | 0.31 | 0.14 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 36.84 | 50.65 |
Angi Inc connects quality home service professionals with consumers across different categories, from repairing and remodeling to cleaning and landscaping. It operates through brands like Angi, HomeAdvisor, and Handy. The company has three operating segments, namely, Ads and Leads, Services, and International (Europe and Canada). A majority of its revenue is generated from the Ads and Leads segment, which provides professionals the capability to engage with potential customers, including quoting and invoicing services, and provides consumers with tools and resources to help them find professionals nationwide for home repair, maintenance, and improvement projects. Geographically, the company derives its key revenue from the United States and also has a presence in other countries.
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.